Leap Therapeutics (NASDAQ:LPTX – Get Free Report) and ObsEva (NASDAQ:OBSV – Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.
Institutional & Insider Ownership
30.5% of Leap Therapeutics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 4.3% of Leap Therapeutics shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations and price targets for Leap Therapeutics and ObsEva, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Leap Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| ObsEva | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares Leap Therapeutics and ObsEva’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Leap Therapeutics | N/A | -247.44% | -146.51% |
| ObsEva | N/A | -416.36% | -92.01% |
Risk and Volatility
Leap Therapeutics has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.
Earnings & Valuation
This table compares Leap Therapeutics and ObsEva”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Leap Therapeutics | N/A | N/A | -$67.56 million | ($1.22) | -1.68 |
| ObsEva | N/A | N/A | -$58.38 million | ($0.92) | N/A |
Leap Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.
Summary
ObsEva beats Leap Therapeutics on 7 of the 10 factors compared between the two stocks.
About Leap Therapeutics
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
About ObsEva
ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
